Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021.
COVID-19
Households
Kenya
Population-based
Rural
SARS-CoV-2
Serology
Serosurvey
seroprevalence
transmission
urban informal settlement
Journal
Gates open research
ISSN: 2572-4754
Titre abrégé: Gates Open Res
Pays: United States
ID NLM: 101717821
Informations de publication
Date de publication:
2023
2023
Historique:
accepted:
29
09
2023
medline:
22
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
SARS-CoV-2 has extensively spread in cities and rural communities, and studies are needed to quantify exposure in the population. We report seroprevalence of SARS-CoV-2 in two well-characterized populations in Kenya at two time points. These data inform the design and delivery of public health mitigation measures. Leveraging on existing population based infectious disease surveillance (PBIDS) in two demographically diverse settings, a rural site in western Kenya in Asembo, Siaya County, and an urban informal settlement in Kibera, Nairobi County, we set up a longitudinal cohort of randomly selected households with serial sampling of all consenting household members in March and June/July 2021. Both sites included 1,794 and 1,638 participants in the March and June/July 2021, respectively. Individual seroprevalence of SARS-CoV-2 antibodies was expressed as a percentage of the seropositive among the individuals tested, accounting for household clustering and weighted by the PBIDS age and sex distribution. Overall weighted individual seroprevalence increased from 56.2% (95%CI: 52.1, 60.2%) in March 2021 to 63.9% (95%CI: 59.5, 68.0%) in June 2021 in Kibera. For Asembo, the seroprevalence almost doubled from 26.0% (95%CI: 22.4, 30.0%) in March 2021 to 48.7% (95%CI: 44.3, 53.2%) in July 2021. Seroprevalence was highly heterogeneous by age and geography in these populations-higher seroprevalence was observed in the urban informal settlement (compared to the rural setting), and children aged <10 years had the lowest seroprevalence in both sites. Only 1.2% and 1.6% of the study participants reported receipt of at least one dose of the COVID-19 vaccine by the second round of serosurvey-none by the first round. In these two populations, SARS-CoV-2 seroprevalence increased in the first 16 months of the COVID-19 pandemic in Kenya. It is important to prioritize additional mitigation measures, such as vaccine distribution, in crowded and low socioeconomic settings.
Sections du résumé
Background
UNASSIGNED
SARS-CoV-2 has extensively spread in cities and rural communities, and studies are needed to quantify exposure in the population. We report seroprevalence of SARS-CoV-2 in two well-characterized populations in Kenya at two time points. These data inform the design and delivery of public health mitigation measures.
Methods
UNASSIGNED
Leveraging on existing population based infectious disease surveillance (PBIDS) in two demographically diverse settings, a rural site in western Kenya in Asembo, Siaya County, and an urban informal settlement in Kibera, Nairobi County, we set up a longitudinal cohort of randomly selected households with serial sampling of all consenting household members in March and June/July 2021. Both sites included 1,794 and 1,638 participants in the March and June/July 2021, respectively. Individual seroprevalence of SARS-CoV-2 antibodies was expressed as a percentage of the seropositive among the individuals tested, accounting for household clustering and weighted by the PBIDS age and sex distribution.
Results
UNASSIGNED
Overall weighted individual seroprevalence increased from 56.2% (95%CI: 52.1, 60.2%) in March 2021 to 63.9% (95%CI: 59.5, 68.0%) in June 2021 in Kibera. For Asembo, the seroprevalence almost doubled from 26.0% (95%CI: 22.4, 30.0%) in March 2021 to 48.7% (95%CI: 44.3, 53.2%) in July 2021. Seroprevalence was highly heterogeneous by age and geography in these populations-higher seroprevalence was observed in the urban informal settlement (compared to the rural setting), and children aged <10 years had the lowest seroprevalence in both sites. Only 1.2% and 1.6% of the study participants reported receipt of at least one dose of the COVID-19 vaccine by the second round of serosurvey-none by the first round.
Conclusions
UNASSIGNED
In these two populations, SARS-CoV-2 seroprevalence increased in the first 16 months of the COVID-19 pandemic in Kenya. It is important to prioritize additional mitigation measures, such as vaccine distribution, in crowded and low socioeconomic settings.
Identifiants
pubmed: 37990692
doi: 10.12688/gatesopenres.14684.2
pmc: PMC10661969
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101Subventions
Organisme : Bill & Melinda Gates Foundation
ID : INV-021779
Pays : United States
Organisme : CGH CDC HHS
ID : U01 GH002143
Pays : United States
Organisme : ACL HHS
ID : U01GH002143
Pays : United States
Informations de copyright
Copyright: © 2023 Munywoki PK et al.
Déclaration de conflit d'intérêts
No competing interests were disclosed.
Références
PLoS One. 2012;7(11):e47017
pubmed: 23144796
BMJ Glob Health. 2022 Aug;7(8):
pubmed: 35998978
Lancet Infect Dis. 2020 May;20(5):534-535
pubmed: 32119823
JAMA. 2021 Oct 12;326(14):1436-1438
pubmed: 34473191
Open Forum Infect Dis. 2021 Jun 12;8(7):ofab314
pubmed: 34660838
Acta Biomed. 2021 Oct 01;92(S6):e2021449
pubmed: 34739471
Indian J Med Res. 2021 May&Jun;153(5&6):658-664
pubmed: 34145085
Int J Environ Res Public Health. 2022 Jun 27;19(13):
pubmed: 35805539
Am Stat. 1995 Jan 1;49(1):43-47
pubmed: 24039272
Influenza Other Respir Viruses. 2022 Jan;16(1):7-13
pubmed: 34611986
Lancet Microbe. 2021 Jun;2(6):e240-e249
pubmed: 33778792
Int J Environ Res Public Health. 2021 Jul 27;18(15):
pubmed: 34360241
PLoS One. 2012;7(8):e43656
pubmed: 22937071
Int J Occup Med Environ Health. 2022 Feb 15;35(1):63-74
pubmed: 34524275
Nat Med. 2022 Mar;28(3):496-503
pubmed: 35090165
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
Pediatr Infect Dis J. 2014 Jan;33 Suppl 1:S54-61
pubmed: 24343615
Bull World Health Organ. 2010 Aug 1;88(8):601-8
pubmed: 20680125
Science. 2021 Jan 1;371(6524):79-82
pubmed: 33177105
Front Med (Lausanne). 2021 Jul 16;8:684864
pubmed: 34336891
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
Clin Infect Dis. 2018 Oct 30;67(10):1559-1567
pubmed: 29668861
Am J Trop Med Hyg. 2005 Dec;73(6):1151-8
pubmed: 16354829
Nat Commun. 2021 Jun 25;12(1):3966
pubmed: 34172732
Clin Infect Dis. 2022 Jan 29;74(2):288-293
pubmed: 33893491
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
PLoS One. 2021 Jun 23;16(6):e0252617
pubmed: 34161316
PLoS One. 2022 Oct 14;17(10):e0265478
pubmed: 36240176
PLoS One. 2011 Jan 18;6(1):e16085
pubmed: 21267459
Int J Infect Dis. 2021 Nov;112:25-34
pubmed: 34481966
F1000Res. 2021 Aug 26;10:853
pubmed: 35528961
Emerg Infect Dis. 2023 Jul;29(7):1479-1481
pubmed: 37253276